GILGAMESH PHARMACEUTICALS, INC.

Profile

Company Names

GILGAMESH PHARMACEUTICALS, INC.

Addresses

113 UNIVERSITY PLACE, SUITE 1019, NEW YORK, NY 10003

201 DAM TRAIL #1349, LINVILLE, NC 28646

Phone Numbers

3479676831
347-967-6831

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

2019

State Incorporated:

DELAWARE

Total Amount Raised:

$51,907,691.00

Number of Funding Rounds:

7
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
7
2022-05-16 
$13,761,009.00 
$50,000,001.00 
$36,238,992.00 
Equity 
6
2022-02-04 
$0.00 
$951.00 
$951.00 
Equity 
5
2021-04-26 
$34,701,837.00 
$34,701,891.00 
$54.00 
Equity 
4
2020-09-09 
$735,000.00 
INDEFINITE 
INDEFINITE 
 
3
2020-08-21 
$125,000.00 
INDEFINITE 
INDEFINITE 
 
2
2020-07-21 
$150,000.00 
$150,000.00 
$0.00 
 
1
2020-04-01 
$2,434,845.00 
INDEFINITE 
INDEFINITE 
Equity, Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ROBERT 
 
BERMAN 
DIRECTOR
DEAL AM, LLC   |  COPYTELE INC   |  GILGAMESH PHARMACEUTICALS, INC.   |  OSMOL THERAPEUTICS, INC.   |  GILGAMESH PHARMA INC.
GAETANO 
 
CRUPI 
DIRECTOR
OCEANIX USA INC.   |  GILGAMESH PHARMACEUTICALS, INC.   |  MYCOWORKS, INC.   |  SHIELD AI INC   |  LAMBDA, INC./DE   |  ALTANA TECHNOLOGIES, INC.   |  GECKO ROBOTICS, INC.   |  OXIDE COMPUTER CO
YONI 
 
FALKSON 
EXECUTIVE OFFICER
GILGAMESH PHARMACEUTICALS, INC.
LASZLO 
 
KISS 
EXECUTIVE OFFICER
GILGAMESH PHARMACEUTICALS, INC.
ANDREW 
 
KRUEGEL 
DIRECTOR, EXECUTIVE OFFICER
GILGAMESH PHARMACEUTICALS, INC.   |  GILGAMESH PHARMA INC.
ANDREW 
 
KRUEGEL, PH.D. 
EXECUTIVE OFFICER
GILGAMESH PHARMACEUTICALS, INC.
AMY 
 
KRUSE 
DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.   |  PARADROMICS, INC.   |  IRIDIA, INC.   |  COGNIXION CORP   |  MORPHOCEUTICALS, INC.   |  SATORI NEURO PARTNERS LP   |  MOTIF NEUROTECH, INC.   |  SATORI NEURO CO-INVEST LP   |  GILGAMESH PHARMA INC.
GERARD 
 
MAREK 
EXECUTIVE OFFICER
GILGAMESH PHARMACEUTICALS, INC.
THOMAS 
KEVIN 
MURPHY 
EXECUTIVE OFFICER
GILGAMESH PHARMACEUTICALS, INC.
THOMAS 
KEVIN 
MURPHY, PH.D. 
EXECUTIVE OFFICER
GILGAMESH PHARMACEUTICALS, INC.
DALIBOR 
 
SAMES 
DIRECTOR
KURES INC.   |  GILGAMESH PHARMACEUTICALS, INC.
PHIL 
 
SKOLNICK 
DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.   |  GILGAMESH PHARMA INC.
JONATHAN 
 
SPORN 
EXECUTIVE OFFICER, DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.   |  GILGAMESH PHARMA INC.
JONATHAN 
 
SPORN, M.D. 
EXECUTIVE OFFICER, DIRECTOR
GILGAMESH PHARMACEUTICALS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2022-05-19
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2022-05-16 
2022-02-18
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2022-02-04 
2021-05-06
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2021-04-26 
2020-09-15
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2020-09-09 
2020-08-31
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2020-08-21 
2020-07-22
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2020-07-21 
2020-07-10
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2020-04-01 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#